Figure 5: SMAD7 rescued the effect of miR-182 in TGFβ-induced EMT and osteoclastogenesis. | Nature Communications

Figure 5: SMAD7 rescued the effect of miR-182 in TGFβ-induced EMT and osteoclastogenesis.

From: MicroRNA-182 targets SMAD7 to potentiate TGFβ-induced epithelial-mesenchymal transition and metastasis of cancer cells

Figure 5

(a) Protein levels of EMT markers and SMAD7 in EpRas with TGFβ stimulation, miR-182 inhibition and SMAD7 silencing. (b) EMT morphological changes of EpRas with TGFβ stimulation, miR-182 inhibition and SMAD7 silencing. (c) Transwell invasion of SCP28 with TGFβ stimulation, miR-182 and SMAD7 overexpression (n=4). (d) SBE luciferase reporter assays of HeLa cells with TGFβ stimulation, miR-182 and SMAD7 overexpression (n=4). (e) Osteoclastogenesis of primary bone marrow in conditioned medium of SCP28 with miR-182 and SMAD7 overexpression. Tumour cells were treated with TGFβ, followed by conditioned medium harvest and primary bone marrow culture. The peptide antagonist PTHLH7-34 (0.5 μM) was added into the bone marrow culture (n=4). (f) PTHLH expression in SCP28 treated with TGFβ at different concentration, and the TGFβ inhibitor SB431542 (n=3). Scale bars, 100 μm. *P<0.05, **P<0.01 by student’s t-test. Error bars are defined as s.d.

Back to article page